Ambry Genetics has cataloged all of our tests and organized them below by panel. The comprehensive listing of tests by panel is organized in alphabetical order.
(MUTYH deletion/duplication analysis included for tests ordered 2-10-14 or after)
Familial Adenomatous Polyposis (FAP) is an autosomal dominant colon cancer predisposition syndrome characterized by hundreds to thousands of adenomatous polyps in the internal lining of the colon and the rectum.
BRCAplus is a next generation sequencing (NGS) panel that simultaneously analyzes 5 high-risk breast cancer susceptibility genes, all with published management guidelines.
CancerNext is a next generation sequencing (NGS) panel that simultaneously analyzes 28 genes associated with increased risk for breast, ovarian, colorectal, uterine, and other cancers.
OvaNext is a next generation sequencing (NGS) panel that simultaneously analyzes 23 genes associated with increased risk for breast, ovarian, and/or uterine cancers.
Pancreatitis is characterized by recurring inflammatory attacks that gradually cause irreversible damage to the pancreas and surrounding tissue. Risk factors for pancreatitis range from environmental to genetic.
Hereditary Paraganglioma-Pheochromocytoma (PGL-PCC) Syndrome is characterized by the presence of paragangliomas (PGLs), most often on the head and neck. There are two subtypes of PGLs, sympathetic and parasympathetic paragangliomas.
Primary ciliary dyskinesia (PCD) is a disorder of the lungs and other body systems. It affects an estimated 25,000 Americans of all ethnic backgrounds, many of whom remain undiagnosed. Early diagnosis is instrumental in maintaining well-being and reducing long-term health problems.
Genetic disorders of surfactant dysfunction are lung disorders that can cause breathing problems that vary widely in severity. Often times, these concerns can impact infants immediately after birth; they can benefit from a quick and accurate diagnosis to help direct clinical care.
Ambry's XLID Next-Gen Panel™ utilizes massive parallel sequencing technology to detect point mutations, small insertions and deletions in 81 genes implicated in X-linked intellectual disability.
Next-Gen Sequencing utilizes a massive parallel sequencing technology that provides high throughput and analytical sensitivity. The Ambry XLMR Next-Gen SuperPanel™ will detect point mutations, small insertions and deletions in 81 genes implicated in XLMR. Approximately 42% of patients with XLMR are anticipated to have mutations in one of 81+ known genes implicated in XLMR.